New drug candidate shows potential to restore vision in people with MS

Researchers at the University of Colorado Anschutz Medical Campus have found a promising drug candidate that could help restore vision in individuals with multiple sclerosis (MS) and other neurological conditions that damage neurons.

Risk adjusted net present value: What is the current valuation of Forte Biosciences’s FB-102?

FB-102 is a monoclonal antibody commercialized by Forte Biosciences, with a leading Phase I program in Celiac Disease.

December 14, 2024

Study unveils critical insights in understanding post-traumatic epilepsy

A new international study has unveiled critical insights in understanding post-traumatic epilepsy (PTE), a condition that can develop following traumatic brain injury. Led by researchers

January 27, 2025

Longtime Sandoz exec announces retirement; Lilly appoints head of India

→ Francisco Ballester is retiring as president, region international at Sandoz on March 1, and Peter Stenico will replace him. Ballester has held this role

February 8, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.